Clinical characteristics and responses of patients with relapsed or refractory high-grade B-Cell lymphoma treated with loncastuximab tesirine in the lotis-2 clinical trial
Authors
Alderuccio, J. P.Ai, W. Z.
Radford, John A
Solh, M.
Ardeshna, K. M.
Lunning, M. A.
Hess, B. T.
Zinzani, P. L.
Stathis, A.
Carlo-Stella, C.
Hamadani, M.
Kahl, B. S.
Ungar, D.
Kilavuz, T.
Yu, E.
Qin, Y.
Caimi, P. F.
Affiliation
Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FLIssue Date
2021
Metadata
Show full item recordCitation
Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, et al. Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial. Blood. 2021 Nov;138. PubMed PMID: WOS:000736413906140.Journal
BloodDOI
10.1182/blood-2021-148730Additional Links
https://dx.doi.org/10.1182/blood-2021-148730Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-148730